Phase I/II Study of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) In Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma

被引：1
|
作者：
Younes, Anas [1 ]
Copeland, Amanda [2 ]
Fanale, Michelle A. [3 ]
Hagemeister, Fredrick [4 ]
Fayad, Luis [5 ]
Pro, Barbara [6 ]
Faria, Silvana C.
Ji, Yuan [7 ]
Medeiros, L. Jeffrey
Berry, Donald A.
Buglio, Daniela [4 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Clin Invest & Translat Res Dept Lymphoma Myeloma, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, MD Anderson Canc Ctr Hymphoma Myeloma, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, MD Anderson Canc Ctr Lymphoma Myeloma, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA
[6] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Div Quantitat Sci, Houston, TX 77030 USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
10.1182/blood.V116.21.1763.1763
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1617 / 1617
页数：1
相关论文
共 50 条
  • [1] Safety and Efficacy of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) in Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma
    Younes, Anas
    Copeland, Amanda
    Fanale, Michelle A.
    Fayad, Luis
    Romaguera, Jorge E.
    Kwak, Larry W.
    Neelapu, Sattva S.
    Hagemeister, Fredrick
    Pro, Barbara
    Faria, Silvana de Castro
    Ji, Yuan
    Berry, Donald
    Buglio, Daniela
    Medeiros, L. Jeffrey
    BLOOD, 2011, 118 (21) : 1588 - 1589
  • [2] Phase I and Pharmacokinetic (PK) Study of Everolimus (RAD001) in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL).
    Ogura, Michinori
    Uchida, Toshiki
    Maruyama, Dai
    Uike, Naokuni
    Choi, Ilseung
    Ishizawa, Kenichi
    Itoh, Kuniaki
    Ando, Kiyoshi
    Taniwaki, Masafumi
    Shimada, Naomi
    Kobayashi, Ken
    Tobinai, Kensei
    BLOOD, 2009, 114 (22) : 682 - 683
  • [3] Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma
    Kensei Tobinai
    Michinori Ogura
    Dai Maruyama
    Toshiki Uchida
    Naokuni Uike
    Ilseung Choi
    Kenichi Ishizawa
    Kuniaki Itoh
    Kiyoshi Ando
    Masafumi Taniwaki
    Naomi Shimada
    Ken Kobayashi
    International Journal of Hematology, 2010, 92 : 563 - 570
  • [4] Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma
    Tobinai, Kensei
    Ogura, Michinori
    Maruyama, Dai
    Uchida, Toshiki
    Uike, Naokuni
    Choi, Ilseung
    Ishizawa, Kenichi
    Itoh, Kuniaki
    Ando, Kiyoshi
    Taniwaki, Masafumi
    Shimada, Naomi
    Kobayashi, Ken
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 92 (04) : 563 - 570
  • [5] A phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed aggressive non-hodgkin lymphoma (NHL)
    Gornet, Michel K.
    Habermann, Thomas M.
    Ansell, Stephen M.
    Micallef, Ivana N.
    Porrata, Luis F.
    Johnston, Patrick B.
    Maurer, Matthew J.
    LaPlant, Betsy
    Kabat, Brian
    Inwards, David J.
    Colgan, Joseph P.
    Call, Timothy
    Markovic, Svetomir
    Zent, Clive S.
    Zeldenrust, Steven R.
    Tun, Han W.
    Witzig, Thomas E.
    BLOOD, 2007, 110 (11) : 44A - 44A
  • [6] Phase I study of oral LBH589 in advanced solid tumours and non-Hodgkin's lymphoma
    Prince, H. M.
    George, D.
    Patnick, A.
    Mita, M.
    Atadja, P.
    Dugan, M.
    Butterfoss, D.
    Culver, K.
    Burris, H. S.
    Beck, J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 107 - 107
  • [7] Oral panobinostat (LBH589), a novel deacetylase inhibitor (DACI), demonstrates clinical activity in relapsed/refractory Hodgkin lymphoma (HL)
    Spencer, A.
    DeAngelo, D. J.
    Prince, H. M.
    Bhalla, K. N.
    Fischer, T.
    Liu, A.
    Parker, K.
    Jalaluddin, M.
    Scott, J. W.
    Ottmann, O. G.
    ANNALS OF ONCOLOGY, 2008, 19 : 128 - 128
  • [8] A phase I trial of bortezomib in combination with everolimus for treatment of relapsed/refractory non-Hodgkin lymphoma
    Hill, Brian T.
    Smith, Mitchell R.
    Shelley, Meredeth
    Jagadeesh, Deepa
    Dean, Robert M.
    Pohlman, Brad
    Sweetenham, John W.
    Bolwell, Brian J.
    Smith, Stephen D.
    LEUKEMIA & LYMPHOMA, 2018, 59 (03) : 690 - 694
  • [9] Phase I Trial of Bortezomib and Everolimus in Relapsed/Refractory Non-Hodgkin Lymphoma
    Hill, Brian T.
    Smith, Mitchell R.
    Mears, Jennifer
    Healy, Amy
    Shelley, Meredeth
    Wyckhouse, Jeanie
    Kakish, Janice
    Jagadeesh, Deepa
    Dean, Robert M.
    Pohlman, Brad
    Smith, Stephen D.
    BLOOD, 2014, 124 (21)
  • [10] Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma
    Dickinson, Michael
    Ritchie, David
    DeAngelo, Daniel J.
    Spencer, Andrew
    Ottmann, Oliver G.
    Fischer, Thomas
    Bhalla, Kapil N.
    Liu, Angela
    Parker, Katie
    Scott, Jeffrey W.
    Bishton, Mark
    Prince, H. Miles
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 147 (01) : 97 - 101
12345